Instrument Inactif

Communiqués KemPharm, Inc. Other OTC

Actions

Produits pharmaceutiques

Communiqués

05/08	Zevra Therapeutics: Q2 Earnings Snapshot	AQ
05/08	Zevra Reports Second Quarter 2026 Financial Results and Corporate Update	AQ
04/08	Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference	AQ
03/08	Zevra Therapeutics Announces Publication of Four-Year Real-World Data from U.S. Early Access Program Evaluating MIPLYFFA® (arimoclomol) in Niemann-Pick Disease Type C (NPC)	AQ
24/07	Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union	AQ
22/07	Zevra Therapeutics Announces Details for Q2 2026 Financial Results Call	AQ
23/06	Zevra Therapeutics Announces Publication of Positive MIPLYFFA® Data from Pediatric Substudy in Infants with Niemann-Pick Disease Type C (NPC)	AQ
11/06	Zevra’s Chief Medical Officer to Step Down for Personal Reasons as Part of Planned Transition	AQ
08/06	Zevra Therapeutics Announces Orange Book Listing of U.S. Patent Strengthening Exclusivity for MIPLYFFA	AQ
29/05	Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)	AQ
12/05	Zevra Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference	AQ
06/05	Zevra Therapeutics: Q1 Earnings Snapshot	AQ
06/05	Zevra Reports First Quarter 2026 Financial Results and Corporate Update	AQ
22/04	Zevra Therapeutics Announces Details for Q1 2026 Financial Results Call	AQ
23/03	Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4)	AQ
20/03	Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)	AQ
16/03	Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million	AQ
09/03	Zevra Therapeutics: Q4 Earnings Snapshot	AQ
09/03	Zevra Reports Fourth Quarter and Full Year 2025 Financial Results	AQ
05/03	Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer	AQ
02/03	Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call	AQ
25/02	Delaware Chancery Court Holds That Grant Of Security Interest Is A "Transfer" – Commave v. Zevra	AQ
25/02	Zevra Therapeutics to Present at the Citizens Life Sciences Conference	AQ
19/02	Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses	NE
18/02	Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses	BU